• Je něco špatně v tomto záznamu ?

Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension

E. Ornstová, J. Tužil, K. Chadimová, T. Mlčoch, T. Doležal

. 2022 ; 22 (8) : 1269-1275. [pub] 20220927

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu systematický přehled, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032419

OBJECTIVES: The comparative efficacy between riociguat and selexipag in patients with pulmonary arterial hypertension (PAH) has never been described in literature. Our aim was to prepare indirect treatment comparison (ITC) to evaluate the cost-effectiveness of riociguat in Czechia. METHODS: A systematic literature review identified two relevant trials with comparable endpoints to inform a Bucher ITC of relative and absolute effects. Given the comparable efficacy of riociguat and selexipag, a cost-minimization analysis (CMA) was conducted. RESULTS: A Bucher ITC provided evidence for the comparable relative efficacy of riociguat defined as the odds of unimproved functional class III 0.761 (95% CI 0.372 to 1.558; p = 0.455) compared to selexipag and a comparable absolute efficacy defined as a difference in the 6-minute walking distance of 10.560 meters (95% CI -10.692 to 31.812; p = 0.330). The CMA identified riociguat as the cost-saving therapy. CONCLUSIONS: Switching to riociguat represents the cost-saving therapy for PAH patients who were inadequately compensated with the PDE5i+ERA therapy. Consequently, riociguat has been introduced to the list of reimbursed medicines in Czechia from October 2021. Based on two global trials, we prepared the first indirect treatment comparison followed with CMA of these therapies that may improve future decision-making for PAH indications.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032419
003      
CZ-PrNML
005      
20230131151416.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14737167.2022.2126833 $2 doi
035    __
$a (PubMed)36121156
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ornstová, Eva $u Value Outcomes, Prague 2, Czech Republic $1 https://orcid.org/0000000155806691
245    10
$a Indirect treatment comparison and cost-minimization analysis of riociguat versus selexipag in patients with pulmonary arterial hypertension / $c E. Ornstová, J. Tužil, K. Chadimová, T. Mlčoch, T. Doležal
520    9_
$a OBJECTIVES: The comparative efficacy between riociguat and selexipag in patients with pulmonary arterial hypertension (PAH) has never been described in literature. Our aim was to prepare indirect treatment comparison (ITC) to evaluate the cost-effectiveness of riociguat in Czechia. METHODS: A systematic literature review identified two relevant trials with comparable endpoints to inform a Bucher ITC of relative and absolute effects. Given the comparable efficacy of riociguat and selexipag, a cost-minimization analysis (CMA) was conducted. RESULTS: A Bucher ITC provided evidence for the comparable relative efficacy of riociguat defined as the odds of unimproved functional class III 0.761 (95% CI 0.372 to 1.558; p = 0.455) compared to selexipag and a comparable absolute efficacy defined as a difference in the 6-minute walking distance of 10.560 meters (95% CI -10.692 to 31.812; p = 0.330). The CMA identified riociguat as the cost-saving therapy. CONCLUSIONS: Switching to riociguat represents the cost-saving therapy for PAH patients who were inadequately compensated with the PDE5i+ERA therapy. Consequently, riociguat has been introduced to the list of reimbursed medicines in Czechia from October 2021. Based on two global trials, we prepared the first indirect treatment comparison followed with CMA of these therapies that may improve future decision-making for PAH indications.
650    _2
$a lidé $7 D006801
650    12
$a plicní arteriální hypertenze $7 D000081029
650    12
$a plicní hypertenze $x farmakoterapie $7 D006976
650    _2
$a náklady a analýza nákladů $7 D003365
650    _2
$a antihypertenziva $7 D000959
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tužil, Jan $u Value Outcomes, Prague 2, Czech Republic $u Medical Informatics, 1st Faculty of Medicine, Charles University in Prague, Czech Republic $1 https://orcid.org/0000000271824010
700    1_
$a Chadimová, Kateřina $u Value Outcomes, Prague 2, Czech Republic $u Institute of Economic Studies, Faculty of Social Sciences, Charles University in Prague, Czech Republic $1 https://orcid.org/0000000176301166
700    1_
$a Mlčoch, Tomáš $u Value Outcomes, Prague 2, Czech Republic $1 https://orcid.org/0000000277168819
700    1_
$a Doležal, Tomáš $u Value Outcomes, Prague 2, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00174435 $t Expert review of pharmacoeconomics & outcomes research $x 1744-8379 $g Roč. 22, č. 8 (2022), s. 1269-1275
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36121156 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151411 $b ABA008
999    __
$a ok $b bmc $g 1891279 $s 1183754
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 22 $c 8 $d 1269-1275 $e 20220927 $i 1744-8379 $m Expert review of pharmacoeconomics & outcomes research $n Expert rev. pharmacoecon. outcomes res. $x MED00174435
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace